In:
Complex Issues of Cardiovascular Diseases, NII KPSSZ, Vol. 10, No. 1 ( 2021-03-24), p. 103-108
Abstract:
The results of the international multicenter study EMPEROR-Reduced have been discussed on October 31, 2020, at the online expert meeting. Considering the positive cardiovascular and renal effects of empagliflozin, the experts have supported the use of empagliflozin in the clinical practice to treat patients with chronic heart failure.
Type of Medium:
Online Resource
ISSN:
2587-9537
,
2306-1278
DOI:
10.17802/2306-1278-2021-10-1-103-108
Language:
Unknown
Publisher:
NII KPSSZ
Publication Date:
2021